In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Watson's Strategy for Beating the Big Boys

Executive Summary

Watson's launch of incontinence drug Oxytrol illustrates the opportunities and challenges specialty pharma companies face when they try to move into primary care markets dominated by Big Pharma. Watson's added a whole set of Big Pharma-experienced managers and is betting that their expertise can guide it through the intimidating process of selecting and launching products. Even so, launching a product into primary care markets requires a commitment that stresses resources and changes the corporate culture.

Related Content

Watson Seeks Partner For Rapaflo: Is There Still A Market For “Me-Too’s”?
Teasing Out Next-Generation Diabetes Drugs
Endo: Accessing Primary Care through Specialist Marketing
Can an Overthrown King Help Mylan?
From Generics to Brands: Barr's Women's Health Franchise
Pliva/Indevus: Moving Up the Value Chain
Sepracor's Primary Care Ambitions
Sepracor's Primary Care Ambitions
A Precarious Union: Combining Proprietary and Generic Businesses
A Precarious Union: Combining Proprietary and Generic Businesses


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts